Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. It seems everyone I know has been getting sick lately — hope you are all taking care of yourselves! Onto the news today.
BridgeBio notches another Phase 3 win
BridgeBio said this morning that its investigational drug succeeded in a late-stage trial of patients with autosomal dominant hypocalcemia type 1, a rare genetic condition that causes low calcium levels in the blood.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply